T he importance of Haemophilus influenzae type b (Hib) as a cause of severe infections in young children is not generally appreciated by health care workers outside children's hospitals or the general public. This is probably because severe Nib disease is largely restricted to young children (at least 90 per cent of cases occur by five years of age), although there have been a number of case series reporting disease in adults,' particularly epiglottitisi' Despite the restricted age group affected, the annual mortality caused by Nib in the US has been calculated as comparable to that of epidemic poliomyehtis in the early 1950ai Universal immunisation against Nib disease has been recommended in a number of countries, including the US (since 1985) and Canada To assess the value to the Australian community of immunisation, data on the costs of Nib disease (which depends on disease incidence and sequelae) and the efficacy, costs and side-effects of the vaccine (which depends on population characteristics and vaccine type) are needed. Decisions about vaccine delivery (universal vs targeted and timing and number of doses) are also important.
EPIDEMIOLOGY OF HIB DISEASE Pattern of fib disease
The epidemiology of invasive Haemophilus disease differs markedly in different geographic areas. The most important differences are the total disease incidence, the age distribution and the proportion of epiglottitis, which are inter-related and have important implications.
The highest reported annual incidence of invasive Hcumophilus disease in the world is that in Central Australian Aboriginal children (900 per 100,000 children under five years). Epiglottitis rarely occurs in these groups, in whom most cases occur in the first six months of life, affecting up to 2 per cent of children by their first birthday. Population-based data on childhood Nib disease show a pattern of Hib disease in urban Australia which resembles that in Scandinavia most closely, with an annual incidence of 30-60 pci-100,000 for all Rib disease with a relatively high incidence of epiglottitis (13-23 per 100,000). Using a mid-range estimate of incidence (40), a minimum of 500 cases occur each year in children under five years in Australia. In a recent study of childhood Hib disease in the greater Sydney metropolitan area, 292 cases in children 0-14 years were identified between 1985 and 1987, an average of about 100 a year.' Meningitis accounted for the majority of cases (51 per cent), and epigiottitis (32 per cent), with the remainder predominantly cellulitis (6 per cent), arthritis (5 per cent) and pneumonia (4 per cent). Most studies from the US report a higher incidence for all Rib disease (60-100 per 100,000) but much less epiglottitis (2-11 per 100,000)i This difference in the incidence of epiglottitis largely explains the differences in age distribution, with 50 per cent of cases being over 24 months in Australia"7 and Finland compared to 20 per cent or fewer in the US. In general, as a higher disease incidence occurs, a lower median age of onset is noted and epigiottitis is found to be relatively less.
Risk factors for Hib disease
Case control studies in the US and Finland have identified day-care outside the home and the presence of young siblings as independent risk factors, whereas breast feeding was protective"°" The interaction of day-care attendance and age differed in two US studies, increasing indirectly with age in Atlanta' but directly with age in Colorado." The attributable risk for Rib disease from day-care was estimated to be 50 per cent in Atlanta There is evidence of genetic differences in susceptibility to Hib disease, as well as differences between strains of Hib, but race and ethnicity were not associated with an increased risk of Hib disease after correction for demographic variables in one studyi' There are differences in the findings and obvious sociodemographic differences between each area and Australia. Case-control studies are in progress in Sydney and Melbourne to evaluate the importance of these and other risk factors in Australia.
PUBLIC HEALTH IMPORTANCE OF HIB DISEASE
The magnitude of Nib as a public health problem depends on its incidence, morbidity and mortality.
Incidence
The reported incidence of Hib disease in urban Australia varies from 30 per 100,000 in Adelaide," to 60 in Victoria and the C-old Coast" and there are also differences in the pattern of disease, with Victoria having a high proportion of epiglottitis. Although some differences may relate to case ascertainment, real differences may exist between urban areas of Australia, in addition to those in rural Aboriginal children, as has been described in New Zealand'4 and the US'.
Mortality
Sudden death before hospital admission occurs in both meningitis" and epiglottitis' and thus mortality will be underestimated if only hospital records are used or if autopsies are not expertly performed. In Sydney in 1985-8 7, an average of two deaths occurred annually, all of which were due to meningitis and occurred before or soon after hospital admission. The case fatality rate may be higher for NSW as a whole, as rapid access to sophisticated medical care, such as is necessary for epiglottitis, is not available in some areas. If the case fatality rates and incidence of disease observed in Victoria' and Sydney' are projected to Australia, a minimum of 13 deaths are estimated to occur each year due to childhood Rib disease in this country.
Short-term morbidity
The short-term morbidity and costs of Nib disease primarily relate to hospitalisation. In Sydney in 1985-87, the mean number of hospital days for meningitis was 15, epiglottitis 5, arthritis 11 and other foci 5, with meningitis accounting for 71 per cent and epigiottitis 16 per cent of the 2916 bed days over this period. However, epiglottitis accounted for more than two-thirds of the 416 intensive-care bed days, whose crude cost is about three times greater than standard hospital days. Long-term morbidity The only published Australian study of post-meningitis morbidity is about 15 years old, included only 14 patients and suggested that significant morbidity was uncommon." However, preliminary follow-up data from the 138 surviving patients with meningitis in Sydney in 1985-87 indicate otherwise. Major morbidity (retardation, profound deafness, hydrocephalus) occurred in 7 per cent of children and less severe deficits (fits, motor problems, unilateral hearing loss) in a further 13 per cent. Learning deficits, behaviour problems and other "soft" neurological problems were not studied. 
HIB VACCINE EFFICACY

VACCINE SIDE-EFFECTS
There are extensive data documenting the safety of PRP vaccine in the US' A Finnish study has shown that PRP-D retains its immunogenicity when given with triple antigen and is associated with a similar incidence of side-effects to triple antigen alone2 The main concern is the induction of a transient fall in antibody levels which has been documented with both the PRP and conjugated vaccines3 Although this maybe associated with a short period of enhanced susceptibility to invasive disease, it is not a significant consideration except in the special situation of an outbreak of Hib disease (eg a day-care centre) where chemoprophylaxis rather than vaccination is indicated, at least initially.
VACCINE COSTS
Vaccine administration differs markedly between States, which can have a substantial impact on costs. However these costs are largely fixed, and as any Hib vaccine could be given within the current schedule, additional administration costs should be minimal. Two cost analyses of PRP vaccine at two years24'25 and one of PRP-D vaccine at 18 months°5 in the US concluded that immunisation was cost-effective. In Australia, the pattern of an older disease peak and greater public funding of vaccination would be expected to make the equation more favourable. The cost of prevention of Nib disease should be put in the context of other potentially vaccine-preventable diseases, such as hepatitis B and varicella, when decisions about funding priorities are made.
CONCLUSIONS
Invasive Hib disease is a common cause of serious morbidity and mortality in Australian children, with an estimated minimum of 500 cases and 13 deaths annually. Protein conjugate vaccines are among the safest. They appear to be highly immunogenic, however good-quality data on effectiveness are available only from Finland and substantial differences may exist between populations in their response to polysaccharide vaccines. One of these conjugate vaccines has recently been licensed for use at two, four and six months in the US; licensing of two such vaccines in Australia is being reviewed. For vaccination against Hib to be effective as a public health measure, it should be introduced in a co-ordinated fashion after consideration of the various competing alternatives, the most prominent of which is vaccination against hepatitis B. Detailed consideration of the costs and benefits of universal as opposed to directed immunisation and specific vaccination schedules, both timing and number of doses, in the context of Australian data is needed.
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